Patent US5842477A successfully refreshed from Google Patents.
US5842477A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for repairing cartilage
Assignee: Smith and Nephew Inc
•
Filing: 1996-02-21
•
Granted: 1998-12-01
•
Expires: 2016-02-21
Abstract
Abstract The present invention relates to methods of making and/or repairing cartilage in vivo comprising implanting into a patient, at a site of cartilage damage or loss, a biocompatible, non-living three-dimensional scaffold or framework structure in combination with periosteal/perichondrial tissue that can be used to hold the scaffold in place and provides a source of chondrocyte progenitor cells, chondrocytes and other stromal cells for attachment to the scaffold in vivo. In addition, a preparation of cells that can include chondrocytes, chondrocyte progenitor cells or other stromal cells is administered, either before, during or after implantation of the scaffold and/or the periosteal perichondrial tissue; the cells are administered directly into the site of the implant in vivo and promote the induction of factors that enhance chondrogenesis and the migration of chondrocytes, progenitor cells and other stromal cells from the adjacent in vivo environment into the scaffold for the production of new cartilage at the site of implantation.
Inventors
- 👤 Gail K. Naughton
- 👤 Jane Willoughby
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:50
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/3834; A61F; A61F2/00; A61F2/02; A61F2/30; A61F2/30756; A61L27/3604; A61L27/3641; A61L27/3645; A61L27/3654; A61L27/3683; A61L27/3687; A61L27/3839; A61L27/3843; A61L27/3852; A61F2002/30001; A61F2002/30003; A61F2002/3006; A61F2002/30062; A61F2002/30108; A61F2002/30199; A61F2002/30766; A61F2210/00; A61F2210/0004; A61F2230/00; A61F2230/0063; A61L2430/00; A61L2430/06; Y; Y10; Y10S; Y10S623/00; Y10S623/902
Claims Analysis
Total Claims: 49
Claim 1
Independent Claim
81 words
A method of producing cartilage at a cartilage defect site in vivo comprising: (a) implanting into the defect site a biocompatible, non- living three-dimensional scaffold structure in combination with periosteal tissue, perichondrial tissue or a combination of said tissues; and (b) separately administering into the defect site a preparation of stromal cells for attachment to the scaffold in vivo and for inducing chondrogenesis or migration of stromal cells from the in vivo environment adjacent to the defect site to the scaffold.
Claim 2
Independent Claim
81 words
A method of producing cartilage at a cartilage defect site in vivo comprising: (a) implanting into the defect site a biocompatible, non- living three-dimensional scaffold structure in combination with periosteal tissue, perichondrial tissue or a combination of said tissues; and (b) separately administering into the defect site a preparation of stromal cells for attachment to the scaffold in vivo and for inducing chondrogenesis or migration of stromal cells from the in vivo environment adjacent to the defect site to the scaffold.
Claim 3
Dependent Claim
30 words
The method of claim 1, wherein the scaffold is implanted into the defect site and the periosteal or perichondrial tissue is placed on top of and adjacent to the scaffold.
Claim 4
Dependent Claim
30 words
The method of claim 1, wherein the periosteal or perichondrial tissue is implanted into the defect site and the scaffold is placed on top of and adjacent to the tissue.
Claim 5
Dependent Claim
33 words
The method of claim 1, wherein the periosteal or perichondrial tissue is situated with respect to the scaffold such that stromal cells from the tissue can migrate from the tissue to the scaffold.
Claim 6
Dependent Claim
27 words
The method of claim 1, wherein the periosteal tissue is situated with respect to the scaffold such that the cambium layer of the tissue faces the scaffold.
Claim 7
Dependent Claim
30 words
The method of claim 1, wherein the perichondrial tissue is situated with respect to the scaffold such that the cambium or inner transition layers of the tissue face the scaffold.
Claim 8
Dependent Claim
23 words
The method of claim 1, wherein the preparation of stromal cells is administered prior to, during or after implantation of the scaffold structure.
Claim 9
Dependent Claim
25 words
The method of claim 1, wherein the preparation of stromal cells is administered prior to, during or after implantation of the periosteal or perichondrial tissue.
Claim 10
Dependent Claim
23 words
The method of claim 1, wherein the preparation of stromal cells is physically placed between the scaffold and the periosteal or perichondrial tissue.
Claim 11
Dependent Claim
15 words
The method of claim 1, wherein the scaffold structure is composed of a biodegradable material.
Claim 12
Dependent Claim
23 words
The method of claim 10, wherein the biodegradable material is polyglycolic acid, polylactic acid, cat gut sutures, cellulose, nitrocellulose, gelatin, collagen or polyhydroxyalkanoates.
Claim 13
Dependent Claim
15 words
The method of claim 1, wherein the scaffold structure is composed of a non-biodegradable material.
Claim 14
Dependent Claim
31 words
The method of claim 12, wherein the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, polyhydroxylakanoate, cotton or a cellulose.
Claim 15
Dependent Claim
11 words
The method of claim 1, wherein the scaffold is a felt.
Claim 16
Dependent Claim
11 words
The method of claim 1, wherein the scaffold is a mesh.
Claim 17
Dependent Claim
16 words
The method of claim 1, wherein the scaffold is treated with ethylene oxide prior to implantation.
Claim 18
Dependent Claim
17 words
The method of claim 1, wherein the scaffold is treated with an electron beam prior to implantation.
Claim 19
Dependent Claim
31 words
The method of claim 1, wherein the scaffold comprises or is modified to contain at least one substance capable of enhancing the attachment or growth of stromal cells on the scaffold.
Claim 20
Dependent Claim
40 words
The method of claim 18, wherein the substance is a bioactive agent selected from the group consisting of cellular growth factors, factors that stimulate migration of stromal cells, factors that stimulate chondrogenesis, factors that stimulate matrix deposition, anti-inflammatories, and immunosuppressants.
Claim 21
Dependent Claim
14 words
The method of claim 19, wherein the bioactive agent is a transforming growth factor-beta.
Claim 22
Dependent Claim
18 words
The method of claim 19, wherein the bioactive agent is a bone morphogenetic protein that stimulates cartilage formation.
Claim 23
Dependent Claim
15 words
The method of claim 19, wherein the bioactive agent further comprises a sustained release formulation.
Claim 24
Dependent Claim
18 words
The method of claim 22 further comprising a biocompatible polymer which forms a composite with the bioactive agent.
Claim 25
Dependent Claim
25 words
The method of claim 23, wherein the biocompatible polymer is selected from the group consisting of polylactic acid, poly(lactic-co-glycolic acid), methylcellulose, hyaluronic acid, and collagen.
Claim 26
Dependent Claim
31 words
The method of claim 18, wherein the substance is selected from the group consisting of collagens, elastic fibers, reticular fibers, heparin sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratin sulfate and hyaluronic acid.
Claim 27
Dependent Claim
32 words
The method of claim 1, further comprising the step of administering to the defect site at least one substance capable of enhancing the attachment or growth of stromal cells on the scaffold.
Claim 28
Dependent Claim
44 words
The method of claim 26, wherein the substance is a bioactive agent selected from the group consisting of cellular growth factors, factors that stimulate migration of stromal cells, factors that stimulate chondrogenesis, factors that stimulate chondrogenesis, factors that stimulate matrix deposition, anti-inflammatories, and immunosuppressants.
Claim 29
Dependent Claim
13 words
The method of claim 27, wherein the substance is a transforming growth factor-beta.
Claim 30
Dependent Claim
18 words
The method of claim 27, wherein the bioactive agent is a bone morphogenetic protein that stimulates cartilage formation.
Claim 31
Dependent Claim
17 words
The method of claim 1, wherein the periosteal or perichondrial tissue is autologous to the defect site.
Claim 32
Dependent Claim
13 words
The method of claim 1, wherein the preparation of stromal cells comprises chondrocytes.
Claim 33
Dependent Claim
15 words
The method of claim 1, wherein the preparation of stromal cells comprises chondrocyte progenitor cells.
Claim 34
Dependent Claim
16 words
The method of claim 1, wherein the preparation of stromal cells comprises fibroblasts or fibroblast-like cells.
Claim 35
Dependent Claim
51 words
The method of claim 1, wherein the preparation of stromal cells comprises a combination of cells selected from the group consisting of chondrocytes, chondrocyte progenitor cells, fibroblasts, fibroblast-like cells, endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells, adipocytes, umbilical cord cells, and bone marrow cells from umbilical cord blood.
Claim 36
Dependent Claim
17 words
The method of claim 1, wherein the preparation of stromal cells comprises at least one bioactive agent.
Claim 37
Dependent Claim
38 words
The method of claim 35, wherein the bioactive agent is selected from the group consisting of cellular growth factors, factors that stimulate migration of stromal cells, factors that stimulate chondrogenesis, factors that stimulate matrix deposition, anti-inflammatories, and immunosuppressants.
Claim 38
Dependent Claim
14 words
The method of claim 36, wherein the bioactive agent is a transforming growth factor-beta.
Claim 39
Dependent Claim
18 words
The method of claim 36, wherein the bioactive agent is a bone morphogenetic protein that stimulates cartilage formation.
Claim 40
Dependent Claim
22 words
The method of claim 1, wherein the stromal cells of the preparation are genetically engineered to produce at least one bioactive agent.
Claim 41
Dependent Claim
38 words
The method of claim 39, wherein the bioactive agent is selected from the group consisting of cellular growth factors, factors that stimulate migration of stromal cells, factors that stimulate chondrogenesis, factors that stimulate matrix deposition, anti-inflammatories, and immunosuppressants.
Claim 42
Dependent Claim
25 words
The method of claim 1, wherein the stromal cells of the preparation are genetically engineered to express a gene that is deficiently expressed in vivo.
Claim 43
Dependent Claim
29 words
The method of claim 1, wherein the stromal cells of the preparation are genetically engineered to prevent or reduce the expression of a gene expressed by the stromal cells.
Claim 44
Dependent Claim
20 words
The method of claim 1, wherein the cartilage defect site is treated to degrade the existing cartilage at the site.
Claim 45
Dependent Claim
22 words
The method of claim 43, wherein the treatment is selected from the group consisting of enzyme treatment, abrasion, debridement, shaving, and microdrilling.
Claim 46
Dependent Claim
29 words
The method of claim 44, wherein the enzyme treatment utilizes at least one enzyme selected from the group consisting of trypsin, chymotrypsin, collagenase, elastase, hyaluronidase, DNAase, pronase and chondroitinase.
Claim 47
Dependent Claim
25 words
The method of claim 43, wherein the cartilage defect site is enzymatically treated prior to implantation of the scaffold or the periosteal or perichondrial tissue.
Claim 48
Dependent Claim
16 words
The method of claim 32 or 34 wherein the chondrocyte progenitor cells comprise mesenchymal stem cells.
Claim 49
Dependent Claim
13 words
The method of claim 19, 27 or 36 wherein the bioactive agent is
References Cited (Backward Citations)
US4520821A
Cited
US4609551A
Cited
US5510254A
Cited
US5160490A
Cited
US5541107A
Cited
US5518915A
Cited
US5516681A
Cited
US5266480A
Cited
US5443950A
Cited
US5512475A
Cited
US5041138A
Cited
US4963489A
Cited
US4846835A
Cited
US5460959A
Cited
US5032508A
Cited
US5376118A
Cited
US5226914A
Cited
US5197985A
Cited
WO1993015694A1
Cited
US5478739A
Cited
US5723331A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-11-30 | 2002-06-01 | 2002-12-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-11-30 | 2006-06-01 | 2006-12-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-11-30 | 2010-06-01 | 2010-12-01 | $7700.00 | Window Closed / Lapsed |